Prota Theraputics

DEVELOPING A NOVEL APPROACH TO ALLERGEN IMMUNOTHERAPY
Prota Theraputics
Operating

Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel combination probiotic allergen oral immunotherapy treatments. Prota holds an exclusive license to the patented probiotic food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures' Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment. This has enabled Prota to advance their clinical program, develop scalable cGMP product manufacturing processes, and initiate discussions with regulatory agencies in the lead up to a planned large-scale pivotal Phase 3 efficacy and safety study for the PRT100 peanut allergy treatment.

Accelerators
2018 (Life Sciences)
Accelerator

SBE Australia

Images
Taken on 2021-01
Blog Posts
4th December, 2018
Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

20th November, 2018
News article

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque non nunc scelerisque, aliquam ...

20th November, 2018
Development 2017 A

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque non nunc scelerisque, aliquam ...

20th November, 2018
Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

 Location
Melbourne
 People
 Tags
#medical research
#medtech
 Feedback